Loading
Led CheckMate 743, the trial that gave mesothelioma its first new first-line therapy in 16 years.
Paul Baas was principal investigator of CheckMate 743, which showed nivolumab plus ipilimumab improves overall survival over platinum-pemetrexed in unresectable malignant pleural mesothelioma, the first positive first-line trial since 2004 and the basis for immunotherapy's approval in the disease. He has led ESMO and IASLC mesothelioma guidelines and chaired the IASLC mesothelioma staging work.
Shares Mesothelioma, Nivolumab, PD-1, Immune checkpoint inhibitors and the tags mesothelioma, immunotherapy.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
Shares Mesothelioma, Immune checkpoint inhibitors and the tags mesothelioma, immunotherapy.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1.
Shares CheckMate 743, Mesothelioma, Ipilimumab, Nivolumab.
Shares CTLA-4, Ipilimumab, Nivolumab, PD-1 and the tag immunotherapy.
Shares the tags mesothelioma, immunotherapy.
Shares Ipilimumab, Nivolumab, PD-1, Immune checkpoint inhibitors and the tag immunotherapy.